Related information about Entrectinib/Luo Shengquan Capsules

Entrectinib (Entrectinib) is an oral multi-target tyrosine kinase inhibitor, mainly used to treat patients with NTRK fusion, ROS1 or ALK-positive advanced solid tumors and non-small cell lung cancer . The capsule dosage form facilitates long-term administration by patients in a home environment and reduces the inconvenience of intravenous medication. The domestic market specifications are: 100mg 30 capsules and 200mg 90 capsules. Patients can adjust the dosage under the guidance of a doctor according to their weight and condition.

Enrectinib blocks key pathways for cancer cell proliferation and survival by inhibitingNTRK, ROS1 and ALK kinase activities. Its drug distribution characteristics allow it to cross the blood-brain barrier, which has obvious advantages for patients with brain metastases. This is a therapeutic effect that is difficult to fully achieve by other ALK or ROS1 inhibitors. The oral capsule form is not only convenient for daily management, but also ensures stable blood concentration, thereby maintaining sustained anti-tumor activity.

When using entrectinib, you should follow your doctor's individualized regimen. The dosage is usually taken orally once daily and is adjusted based on body weight, liver and kidney function, and concomitant medications. In terms of drug interactions, simultaneous use with potent CYP3A4 inhibitors or inducers should be avoided to ensure efficacy and safety. Common adverse reactions include fatigue, nausea, constipation, edema, mild abnormalities in hematological indicators, etc. In most cases, they can be controlled through dose adjustment or symptomatic treatment.

Looking at global trends, the problem of drug resistance is driving the further development of precision medicine. Some new dual-target inhibitors and combination drug strategies are undergoing clinical trials, and are expected to break through the limitations of entrectinib alone in the future. At the same time, real-world research is constantly accumulating more data on drug resistance patterns to provide more practical reference for clinical practice.

Overall, entrectinib capsules are convenient and highly accessible, suitable for long-term oral treatment, and have obvious advantages in brain metastasis control and multi-target effects, providing an important targeted therapy option for patients with advanced tumors.

Reference materials:https://www.roche.com/products/rozlytrek